Oral Presentation ESA-SRB-APEG-NZSE 2022
Intensive management from diagnosis improves HbA1c at 12 months post diagnosis results from a prospective cohort study in newly diagnosed children with type 1 diabetes (#5)
Background: Intensive management is known to improve long term outcomes in type 1 diabetes, however there is a lack of data to document the impact of this when instituted from diagnosis.
Aim: To examine the impact of intensive management of type 1 diabetes from diagnosis on HbA1c 12 months from diagnosis
Methods: A prospective, continuous cohort of 70 sequentially newly diagnosed children (diagnosed July 2018- November 2021) were reviewed 12 months after diagnosis following implementation of an intensive management protocol from diagnosis and was compared to a retrospective cohort of the previous 70 children diagnosed pre-implementation (diagnosed December 2015- June 2018). Intensive management involved carbohydrate counting and flexible insulin dosing from first meal on sub-cutaneous insulin, targeted blood glucose levels from 4 – 8mmol/L irrespective of time of day, avoidance of twice daily insulin regimens, and promotion of continuous glucose monitoring (unfunded). Baseline demographics of both cohorts were documented, and 12 month data on HbA1c, diabetes technology use, and insulin regimen were compared.
Results: Table 1 documents the baseline and 12-month data of the two cohorts. There was an 11mmol/mol (0.7%) difference between the HbA1c at 12 months between the two groups 12 months.
Conclusion: Intensive management from diagnosis improves long term HbA1c in children with type 1 diabetes. Whilst there have been improvements over all ethnic groups, more is needed to be done in improving outcomes and access to CGM for minority ethnic groups.
